SynthesisInternational journal of molecular sciences2022
COVID-19 and the Immune Response: A Multi-Phasic Approach to the Treatment of COVID-19.
Synthesis in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 34 citations in OpenAlex.
- Selected Cannabinoids, Cannabimimetic Agents andPharmaceuticals (Basel, Switzerland) · 2026Review
- Exploring phenotype-related single-cells through attention-enhanced representation learning.Genome medicine · 2026Article
- Understanding capability, opportunity, and motivation for at-home COVID-19 testing in underserved populations during the pandemic.Translational behavioral medicine · 2026Article
- Physical activity during COVID-19 pandemic: A 5-year retrospect.Sports medicine and health science · 2025Review
- Vaccine-induced immunity is maintained in glioma patients relative to other solid tumours.Journal of neuro-oncology · 2025Article
- Lower serum GPX4 and GSH/GSSG ratio are associated with poor prognosis in severe community-acquired pneumonia.European journal of medical research · 2025Article
- Transcriptomic analysis of differential expression between surviving and nonsurviving patients infected by the SARS-CoV-2 Delta variant.Scientific reports · 2025Article
- Efficient discovery of frequently co-occurring mutations in a sequence database with matrix factorization.PLoS computational biology · 2025Article
- Immune response dynamics to SARS-CoV-2 in the Albanian population: A study on T-cell and antibody interactions during the transition from pandemic to endemic phase.Infectious diseases & immunity · 2025Article
- The Role of Memory T-Cell Mediated Immunity in Long-term COVID-19: Effects of Vaccination Status.Iranian journal of medical sciences · 2025Review
- Post-pandemic insights on COVID-19 and premature ovarian insufficiency.Open life sciences · 2025Review
- Impact of vitamin D on COVID-19 and other viral diseases.World journal of virology · 2024Article
- TRIM7 ubiquitinates SARS-CoV-2 membrane protein to limit apoptosis and viral replication.Nature communications · 2024Article
- Human E3 ubiquitin ligases: accelerators and brakes for SARS-CoV-2 infection.Biochemical Society transactions · 2024Review
- Immune Profile in COVID-19: Unveiling TInternational journal of molecular sciences · 2024Article
- TRIM7 ubiquitinates SARS-CoV-2 membrane protein to limit apoptosis and viral replication.bioRxiv : the preprint server for biology · 2024Article
- Histopathological impact of SARS-CoV-2 on the liver: Cellular damage and long-term complications.World journal of gastroenterology · 2024Review
- Article
- Investigating the structural network underlying brain-immune interactions using combined histopathology and neuroimaging: a critical review for its relevance in acute and long COVID-19.Frontiers in psychiatry · 2024Review
- Advances in attractive therapeutic approach for macrophage activation syndrome in COVID-19.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a viral agent that causes Coronavirus disease 2019 (COVID-19), a disease that causes flu-like symptoms that, when exacerbated, can have life-threatening consequences. COVID-19 has been linked to persistent symptoms, sequelae, and medical complications that can last months after the initial infection. This systematic review aims to elucidate the innate and adaptive immune mechanisms involved and identify potential characteristics of COVID-19 pathology that may increase symptom duration. We also describe he three different stages of COVID-19-viral replication, immune hyperactivation, and post-acute sequelae-as well as each phase's corresponding immune response. Finally, we use this multiphasic approach to describe different treatment approaches for each of the three stages-antivirals, immunosuppressants and monoclonal antibodies, and continued immunosuppressants-to fully curate the treatment to the stage of disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.